Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar

 
• By Bridget Silverman

Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.

T cell and pipette
Cancer is poised to remain the dominate approval category in 2024. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers